Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia.

Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia. Intern Med. 2020 Feb 01;: Authors: Isomoto K, Baba T, Sekine A, Aiko N, Ogura T Abstract We herein report a case of refractory chronic eosinophilic pneumonia (CEP) complicated with uncontrolled bronchial asthma, in which remission was successfully induced with single dose of benralizumab, a monoclonal antibody against the alpha-chain of the interleukin-5 receptor. Resolution of the patient's symptoms and consolidation on chest X-ray were observed at 2 weeks and lasted for 8 weeks after the administration of benralizumab. Benralizumab would be a novel alternative choice of treatment for CEP patients who are at risk of potential toxicity due to long-term corticosteroid therapy. PMID: 32009090 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research